A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy.
OBJECTIVE
1. To compare the effects of 25 mg and 50 mg oestradiol implants on serum follicle stimulating hormone and oestradiol levels; and 2. to assess the relationship of the dose of oestradiol implant and serum oestradiol on the effectiveness and duration of climacteric symptom control.


METHODS
Randomised, double-blind investigation.


METHODS
Forty-four women, who had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy.


METHODS
The women were randomised to receive either 25 mg (n = 20) or 50 mg (n = 24) oestradiol implants. Follow up consisted of prospective symptom enquiry and hormone assays.


METHODS
Primary: climacteric symptom control: duration and effectiveness; secondary: serum oestradiol and follicle stimulating hormone levels.


RESULTS
Serum oestradiol was significantly higher and serum follicle stimulating hormone significantly lower after the fourth month of treatment in women receiving 50 mg implants. No significant difference in symptom control was noted in the two groups. The mean duration of symptom control was similar in the two groups: 5.9 months (SD 2.4) in those receiving 50 mg oestradiol and 5.6 months (SD 2.3) in those receiving 25 mg.


CONCLUSIONS
The higher level, 50 mg oestradiol implants does not result in better control of symptoms nor in longer periods of symptom control compared with 25 mg oestradiol implants. In order to maximise compliance, 25 mg oestradiol implants should therefore be the treatment of choice for women with normal bone density seeking relief of climacteric symptoms.
Panay
N
N
Department of Obstetrics and Gynaecology, University Hospital Lewisham, London.
Versi
E
E
Savvas
M
M
D002979:Climacteric / Q000187:drug effects*; D004311:Double-Blind Method; D004343:Drug Implants / Q000627:therapeutic use*; D004958:Estradiol / Q000008:administration & dosage* / Q000097:blood; D015914:Estrogen Replacement Therapy / Q000379:methods; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects*; D008875:Middle Aged; D010052:Ovariectomy / Q000009:adverse effects* / Q000379:methods
D004343:Drug Implants; D004958:Estradiol; D005640:Follicle Stimulating Hormone